Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.74 |
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590291 | 0.84 | NPC1 (0.75) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12579765 | 0.83 | NPC1 (0.75) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4015642 | 0.83 | NPC1 (0.73) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL31752862 | 0.82 | NPC1 (0.73) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL23884739 | 0.81 | NPC1 (0.71) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18131134 | 0.81 | NPC1 (0.71) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL25442203 | 0.81 | NPC1 (0.71) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31753039 | 0.81 | NPC1 (0.71) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2667078 | 0.81 | NPC1 (0.66) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18421576 | 0.80 | NPC1 (0.65) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | claimed |
| JP-4651714-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| EP-1915367-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | claimed |
| EP-1856056-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | claimed |
| EP-1802582-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME. | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | claimed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| WO-2006040528-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | claimed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | claimed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | claimed |
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |
| EP-1915367-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1802582-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME. | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |